Three drugs to watch

**Tecartus™**

Tecartus is a cell therapy called CAR T that leverages the immune system to attack cancer cells.

Tecartus is the first CAR T therapy for a rare and aggressive cancer called mantle cell lymphoma (MCL) with a list price of $373,000, similar to other CAR T drugs. It will compete against five less-expensive drugs for MCL, however, Tecartus was effective in patients who had already failed other treatments.

**Kesimpta®**

Kesimpta is used to treat the most common (“relapsing”) form of multiple sclerosis (MS).

Kesimpta enters a crowded MS marketplace, with multiple well established products. Its simple, self-administered injection dosed once every month after initial dosing may offer an advantage. Kesimpta is priced at $83,000 per year. Competitors Ocrevus® and Aubagio® cost $65,000 and $93,000 per year, respectively.

**Monjuvi®**

Monjuvi is a new treatment option for patients with the most common type of non-Hodgkin lymphoma – diffuse large B-cell lymphoma (DLBCL).

Monjuvi targets the same cancer protein as existing CAR-T therapies, but is not a CAR T. So Monjuvi may help patients not eligible for CAR T, while avoiding their inherent risk, cost and delays. [See “Industry Trend to Watch” in the full report.]

Monjuvi launched at $198,000 compared to CAR-T treatments priced between $373,000 and $475,000.